- Home
- CRSP vs BWIN Comparison
CRSP vs BWIN Comparison
Compare CRSP & BWIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- BWIN
- Stock Information
- Founded
- CRSP 2013
- BWIN 2011
- Country
- CRSP Switzerland
- BWIN United States
- Employees
- CRSP N/A
- BWIN N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- BWIN Specialty Insurers
- Sector
- CRSP Health Care
- BWIN Finance
- Exchange
- CRSP Nasdaq
- BWIN Nasdaq
- Market Cap
- CRSP 3.3B
- BWIN 3.0B
- IPO Year
- CRSP 2016
- BWIN 2019
- Fundamental
- Price
- CRSP $36.29
- BWIN $38.53
- Analyst Decision
- CRSP Buy
- BWIN Buy
- Analyst Count
- CRSP 16
- BWIN 8
- Target Price
- CRSP $73.07
- BWIN $44.86
- AVG Volume (30 Days)
- CRSP 2.1M
- BWIN 521.4K
- Earning Date
- CRSP 05-06-2025
- BWIN 05-06-2025
- Dividend Yield
- CRSP N/A
- BWIN N/A
- EPS Growth
- CRSP N/A
- BWIN N/A
- EPS
- CRSP N/A
- BWIN N/A
- Revenue
- CRSP $37,675,000.00
- BWIN $1,422,075,000.00
- Revenue This Year
- CRSP $26.79
- BWIN $12.67
- Revenue Next Year
- CRSP $297.32
- BWIN $13.93
- P/E Ratio
- CRSP N/A
- BWIN N/A
- Revenue Growth
- CRSP N/A
- BWIN 12.11
- 52 Week Low
- CRSP $30.04
- BWIN $31.47
- 52 Week High
- CRSP $67.88
- BWIN $55.82
- Technical
- Relative Strength Index (RSI)
- CRSP 46.12
- BWIN 44.16
- Support Level
- CRSP $35.38
- BWIN $37.95
- Resistance Level
- CRSP $38.13
- BWIN $39.28
- Average True Range (ATR)
- CRSP 1.73
- BWIN 1.15
- MACD
- CRSP -0.03
- BWIN 0.06
- Stochastic Oscillator
- CRSP 26.30
- BWIN 42.28
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About BWIN The Baldwin Insurance Group Inc. Class A Common Stock
The Baldwin Insurance Group Inc is a United States-based insurance distribution firm. Its products include Business Insurance, Benefits Consulting, Reinsurance, Specialty MGA, Embedded Insurance., Personal insurance, etc.